Biopharma Business

Tag "Novartis"

Novartis’ Swiss head of operations reveals job cuts

    Novartis’ Swiss head of operations reveals job cuts

Novartis has revealed that up to 500 positions in Switzerland will be eliminated or transferred to other areas over the next 18 months, but will counterbalance that with 350 new

Read Full Article

Allergan and Novartis Collaborate on Multi-Therapy Treatment for NASH

Allergan, a global biopharmaceutical company, announced that it has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan’s cenicriviroc (CVC) and Novartis’ lead FXR

Read Full Article

Novartis’ lung cancer drug combination receives EU approval

The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC). The

Read Full Article

Novartis puts the Development of two Anti-Aging Drugs in American Hands

PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio

Read Full Article

British Biotech’s Breast Cancer Drug gets FDA Approval for Novartis

Novartis has received FDA approval for Kisqali, a first-line treatment for breast cancer originally developed by the British biotech Astex Pharmaceuticals. The oncology company Astex Pharmaceuticals, located in Cambridge’s biotech hub, entered

Read Full Article

Novartis, NHS joint working pact delivers new eye service

People living in Ayrshire and Arran who have some of the most common forms of avoidable sight loss will now be able to benefit from a new facility designed specifically

Read Full Article

What Happened to the Smart Contact Lens for Diabetics?

Originally projected to be on the market by 2020, excitement about the contact lens to measure glucose levels from Novartis and Google has waned. Why? In 2016, smart wearables growth was steady but

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here